Savara Inc. (NASDAQ:SVRA) has seen positive outlook with price target increase to $11. Analysts predict high demand for Molbreevi, indicating potential for blockbuster sales. The company focuses on rare respiratory diseases, offering promising investment opportunities.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing